NTLA - BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)

2024-06-03 14:14:05 ET

Summary

• BridgeBio Pharma, Inc. stock has fallen by 10% since December, but recent trial data and analyst support have boosted investor enthusiasm recently.
• The company's primary drug candidate, Acoramidis, has a marketing application accepted by the FDA for review, with a decision expected in November.
• Acoramidis could have significant peak sales potential in the rapidly growing ATTR-CM market.
• An updated analysis of BridgeBio Pharma follows in the paragraphs below.

When we last looked at BridgeBio Pharma, Inc. ( BBIO ) back in early December of last year, the stock had recently doubled. Our advice after that article was to take at least some profits, as the shares seemed to have gotten a bit ahead of themselves....

For further details see: